Avalo Therapeutics reported positive Phase 2 results for Abdakibart, their lead antibody treatment candidate targeting hidradenitis suppurativa (HS). The results support moving forward to a pivotal trial, with Abdakibart's monthly dosing offering a potential advantage in HS treatment. While another drug, Lutikizumab, showed modest Phase 3 benefits that somewhat challenge Abdakibart's outlook, Avalo's strong balance sheet provides the financial runway to meet upcoming milestones. Another candidate, AVTX-010, is still years away from becoming a significant value driver due to its planned IND submission timeline. Overall, the recent stock pullback may present a good entry point for investors betting on Abdakibart's potential.
Avalo Therapeutics and its lead antibody candidate Abdakibart provide context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Oct 25, 2026 11:01 WIB: out of 150 priced US health-sector stocks, 44 rose and 105 fell. Notable movers include HIMS at USD 27.71 with a 1-day change of -4.87% and Pluang order activity showing 75% Sell / 25% Buy, AMLX at USD 27.20 down 4.80%, and TVTX at USD 50.05 down 4.54%, with typical hold times ranging from 10 to 22 days on Pluang.
Hedera's HBAR token price fell 8.8% over the past week to $0.0785, driven mainly by a lack of new investment inflows rather than large sell-offs. The American spot ETF on HBAR holds $62.57 million, down due to price declines, not withdrawals. In Nove...
Binance's spot market currently has $14.69 million in sell orders compared to $9.38 million in buy orders, creating a $5.31 million gap favoring sellers. Coinbase also shows more sell orders than buy orders, but with a smaller difference. This imbala...
Bitcoin is trading near $80,853 with minimal movement, slightly below its 50-day moving average of $81,807, signaling potential resistance. Key events this week include the Federal Reserve's rate decision expected to hold steady, and a significant $1...
OpenFour, part of Four.Meme, launched Binance Agent ID Exclusive, a new token launch format that raises funds in BNB and restricts early trading to Binance Agentic Wallets verified by Agent ID. During the bonding-curve phase, wallets can hold up to 1...
Sygnum has introduced a new Bitcoin loan service called MultiSYG, which uses a unique system where Bitcoin collateral keys are distributed among the clients, the bank, and independent institutional key holders. This approach enhances security by ensu...
